202 related articles for article (PubMed ID: 11348726)
1. Vaccine regimen for prevention of sexually transmitted infections with human papillomavirus type 16.
Kowalczyk DW; Wlazlo AP; Shane S; Ertl HC
Vaccine; 2001 May; 19(25-26):3583-90. PubMed ID: 11348726
[TBL] [Abstract][Full Text] [Related]
2. Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies.
Kawana K; Kawana Y; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
Vaccine; 2001 Jan; 19(11-12):1496-502. PubMed ID: 11163673
[TBL] [Abstract][Full Text] [Related]
3. Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines.
Chen CH; Wang TL; Hung CF; Pardoll DM; Wu TC
Vaccine; 2000 Apr; 18(19):2015-22. PubMed ID: 10706963
[TBL] [Abstract][Full Text] [Related]
4. Papillomavirus-like particle vaccines.
Schiller JT; Lowy DR
J Natl Cancer Inst Monogr; 2001; (28):50-4. PubMed ID: 11158207
[TBL] [Abstract][Full Text] [Related]
5. Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice.
Revaz V; Benyacoub J; Kast WM; Schiller JT; De Grandi P; Nardelli-Haefliger D
Virology; 2001 Jan; 279(1):354-60. PubMed ID: 11145916
[TBL] [Abstract][Full Text] [Related]
6. Parenteral and oral immunization with a plasmid DNA expressing the human papillomavirus 16-L1 gene induces systemic and mucosal antibodies and cytotoxic T lymphocyte responses.
Rocha-Zavaleta L; Alejandre JE; Garcia-Carranca A
J Med Virol; 2002 Jan; 66(1):86-95. PubMed ID: 11748663
[TBL] [Abstract][Full Text] [Related]
7. Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems.
Park JS; Oh YK; Kang MJ; Kim CK
J Med Virol; 2003 Aug; 70(4):633-41. PubMed ID: 12794729
[TBL] [Abstract][Full Text] [Related]
8. DNA vaccination of mice with plasmid expressing human papillomavirus 6 major capsid protein L1 elicits type-specific antibodies neutralizing pseudovirions constructed in vitro.
Matsumoto K; Kawana K; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
J Med Virol; 2000 Feb; 60(2):200-4. PubMed ID: 10596021
[TBL] [Abstract][Full Text] [Related]
9. Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes.
Dupuy C; Buzoni-Gatel D; Touzé A; Bout D; Coursaget P
J Virol; 1999 Nov; 73(11):9063-71. PubMed ID: 10516012
[TBL] [Abstract][Full Text] [Related]
10. Developments in L2-based human papillomavirus (HPV) vaccines.
Schellenbacher C; Roden RBS; Kirnbauer R
Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
[TBL] [Abstract][Full Text] [Related]
11. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice.
Ohlschläger P; Osen W; Dell K; Faath S; Garcea RL; Jochmus I; Müller M; Pawlita M; Schäfer K; Sehr P; Staib C; Sutter G; Gissmann L
J Virol; 2003 Apr; 77(8):4635-45. PubMed ID: 12663770
[TBL] [Abstract][Full Text] [Related]
13. Production of human papillomavirus type 16 virus-like particles in transgenic plants.
Biemelt S; Sonnewald U; Galmbacher P; Willmitzer L; Müller M
J Virol; 2003 Sep; 77(17):9211-20. PubMed ID: 12915537
[TBL] [Abstract][Full Text] [Related]
14. Papillomavirus-like particles for serology and vaccine development.
Kirnbauer R
Intervirology; 1996; 39(1-2):54-61. PubMed ID: 8957670
[TBL] [Abstract][Full Text] [Related]
15. The L1 major capsid protein of human papillomavirus type 16 variants affects yield of virus-like particles produced in an insect cell expression system.
Touze A; El Mehdaoui S; Sizaret PY; Mougin C; Muñoz N; Coursaget P
J Clin Microbiol; 1998 Jul; 36(7):2046-51. PubMed ID: 9650960
[TBL] [Abstract][Full Text] [Related]
16. Protection against papillomavirus with a polynucleotide vaccine.
Donnelly JJ; Martinez D; Jansen KU; Ellis RW; Montgomery DL; Liu MA
J Infect Dis; 1996 Feb; 173(2):314-20. PubMed ID: 8568291
[TBL] [Abstract][Full Text] [Related]
17. Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model.
Monroy-García A; Gómez-Lim MA; Weiss-Steider B; Hernández-Montes J; Huerta-Yepez S; Rangel-Santiago JF; Santiago-Osorio E; Mora García Mde L
Arch Virol; 2014 Feb; 159(2):291-305. PubMed ID: 23990055
[TBL] [Abstract][Full Text] [Related]
18. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
Pouyanfard S; Spagnoli G; Bulli L; Balz K; Yang F; Odenwald C; Seitz H; Mariz FC; Bolchi A; Ottonello S; Müller M
J Virol; 2018 Feb; 92(4):. PubMed ID: 29212932
[TBL] [Abstract][Full Text] [Related]
19. Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1.
Kuck D; Lau T; Leuchs B; Kern A; Müller M; Gissmann L; Kleinschmidt JA
J Virol; 2006 Mar; 80(6):2621-30. PubMed ID: 16501072
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice.
Nardelli-Haefliger D; Roden RB; Benyacoub J; Sahli R; Kraehenbuhl JP; Schiller JT; Lachat P; Potts A; De Grandi P
Infect Immun; 1997 Aug; 65(8):3328-36. PubMed ID: 9234794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
